search
Back to results

Community-Acquired Pneumonia : Evaluation of Corticosteroids (CAPE_COD)

Primary Purpose

Community Acquired Pneumonia

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Hydrocortisone
Placebo
Sponsored by
University Hospital, Tours
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Community Acquired Pneumonia focused on measuring Community-Acquired Pneumonia (CAP), Hydrocortisone, Corticosteroids, COronaVIrus Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Patients affiliated to social security scheme
  • Admission to an Intensive Care Unit (ICU) or intermediate care unit participating to the trial
  • Diagnosis of Community- Acquired Pneumonia (CAP) suggested by at least two of the following: cough, purulent sputum, chest pain and dyspnea
  • Focal shadowing/infiltrate on chest X-ray or CT-scan
  • Diagnosis of Community- Acquired Pneumonia (CAP) during the 48 hours post-hospital admission
  • Study drug infusion initiated no longer than 24 hours post first severity criterion
  • Severity defined by at least one of the following:

    • Pneumonia Severity Index (PSI) > 130 (Fine class V)
    • Patient placed on mechanical ventilation (invasive or not) for acute respiratory failure, with a PEEP level of 5 cm of water or more
    • Patient treated by high-flow oxygen therapy with a FiO2 of 50% or more and a P/F ratio less than 300
    • Patient treated by oxygen therapy with a partial rebreathing-mask with a reservoir bag, provided that the PaO2 is less than (cf. table):

Oxygen flow (L/min) 6 7 8 9 10 or more PaO2 (mmHg) less than 180 210 240 270 300

  • Patient already treated by antibiotics (at least one dose since admission to hospital)
  • Informed consent signed by the patient, its relatives or emergency procedure

On the sub-group of patients included with COVID19 :

  • Diagnosis of COVID19 either as certain (PCR) or probable (evocative clinical and radiological features AND epidemic context AND absence of other microbiological documentation).
  • Study drug infusion initiated no longer than 24 hours post first severity criterion ; in case of transfer from another hospital, this period will be prolonged to 48 hours
  • Patient receiving the best available treatment as define by up-to-date scientific knowledge

Exclusion Criteria:

  • Patient treated by vasopressors for septic shock at the time of inclusion
  • Clinical history suggesting of aspiration of gastric content
  • Patient treated by invasive mechanical ventilation within 14 days before current hospital admission
  • Patient treated by antibiotics for a respiratory infection for more than seven days at the admission to the hospital (except if a pathogen resistant to this antibiotics is isolated)
  • History of cystic fibrosis
  • Post-obstructive pneumonia
  • Patients in which rapid PCR-test is positive for flu
  • Active tuberculosis or fungal infection
  • Active viral hepatitis or active infection with herpes viruses
  • Myelosuppression
  • Decision of withholding mechanical ventilation or endotracheal intubation
  • Hypersensitivity to corticosteroids
  • Patient needing anti-inflammatory corticosteroids or substitutive hydrocortisone for any reason
  • Patients under treatment by more than 15 mg/d of prednisone (or equivalent) for more than 30 days
  • Patient already enrolled in another drug trial with mortality as an end-point. If the patient is already participating in another therapeutic trial with a different endpoint, the investigator must verify that inclusion in CAPE COD can not prejudice it.
  • Pregnant or breastfeeding woman
  • Patient on judicial protection

Sites / Locations

  • Service de Réanimation - Unité de Soins Continus, CH d'Angoulême
  • Service de Réanimation Polyvalente, CH d'Argenteuil
  • Service de Réanimation, CHR Metz-Thionville
  • Service de Réanimation
  • Service de Réanimation
  • Service de Réanimation
  • Service de Réanimation HIA Clermont-Tonnerre
  • Service de Réanimation Médicale, CHU de Brest
  • Service de Réanimation, CHU Côte de Nacre
  • Service de Réanimation Médicale, Hôpital Louis Pasteur, Chartres
  • Service de Réanimation Médicale Polyvalente, Hôpital G Montpied
  • Service de Réanimation, Hôpital Louis Mourier
  • Service de Réanimation Médicale, CHU de Dijon
  • Service de Réanimation Médico-Chirurgicale, Hôpital Raymond Poincarré, APHP
  • Service de Réanimation Médicale, CHU de Grenoble
  • Service de Réanimation Polyvalente, CHD La Roche sur Yon
  • Service de Réanimation, CH Le Mans
  • Service de Réanimation Polyvalente, Hôpital Salengro, CHU de Lille
  • Service de Réanimation Polyvalente, CHU de Limoges
  • Service de Réanimation Médicale, Hôpital Nord
  • Service de Réanimation Polyvalente - Surveillance Continue, CH de Montauban
  • Service de Réanimation Médicale, CHU de Nancy
  • Service de Réanimation Polyvalente, Hôpital Hôtel Dieu, CHU de Nantes
  • Service de Réanimation Médicale, CHR d'Orléans
  • Service de Réanimation Médicale, Hôpital Cochin, APHP
  • Service de Réanimation et USC médico-chirurgicale, Hôpital Tenon, APHP
  • Service de Réanimation Médicale et Médecine Interne, CHU de Poitiers
  • Service des Maladies Infectieuses et Réanimation Médicale, CHU de Rennes
  • Service de Réanimation Polyvalente, CH de Saint Malo
  • Service de Réanimation
  • Service de Réanimation Médicale, Nouvel Hôpital Civil, CHU de Strasbourg
  • Service de Réanimation Médicale, Hôpital de Hautepierre, CHU de Strasbourg

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Hydrocortisone

Placebo

Arm Description

Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)

Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)

Outcomes

Primary Outcome Measures

Day 28 all causes mortality
Day 21 failure
For the sub-group of patients included with COVID19, failure is defined as death or need of respiratory support (mechanical ventilation or high-flow oxygen therapy);

Secondary Outcome Measures

In patients non-invasively ventilated at inclusion, proportion of patients needing endotracheal intubation
In patients non-ventilated at inclusion, proportion of patients requiring non-invasive ventilation
In patients non-ventilated at inclusion, proportion of patients needing endotracheal intubation
Day 28 ventilator-free-days
Number of patients with vasopressor therapy initiation from inclusion to day 28
Day 28 vasopressor-free-days
ICU and/or intermediate care unit LOS
All-causes mortality at day 90
SF-36 Health Survey at day 90
Biomarkers: procalcitonin at baseline, day 3 and day 7
Biomarkers: C-reactive protein at baseline, day 3 and day 7
Biomarkers: plasmatic concentration of pro-inflammatory cytokines (IL-6, IL-20, IL-22, IL-22BP, HBD2, TNF) at baseline, day 3 and day 7
P/F ratio measured daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28
SOFA calculated daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28
Proportion of patients experiencing secondary infection during their ICU-stay
Proportion of patients experiencing gastrointestinal bleeding during their ICU-stay
Daily amount of insulin administered to the patient from day 1 to day 7
Weight-gain at baseline and day 7

Full Information

First Posted
July 31, 2015
Last Updated
January 9, 2023
Sponsor
University Hospital, Tours
search

1. Study Identification

Unique Protocol Identification Number
NCT02517489
Brief Title
Community-Acquired Pneumonia : Evaluation of Corticosteroids
Acronym
CAPE_COD
Official Title
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
October 28, 2015 (Actual)
Primary Completion Date
July 19, 2020 (Actual)
Study Completion Date
August 28, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Tours

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is between 25 and 30% in sub-groups of patients. Corticosteroids (CTx) could down-regulate pulmonary and systemic inflammation, accelerate clinical resolution and decrease the rate of inflammation-associated systemic complications. Two recent meta-analyses suggest a positive effect on severe CAP day 28 survival when CTx are added to standard therapy. However they are based on only four trials gathering less than 300 patients, of which only one was positive. Recently published guidelines do not recommend CTx as part of CAP treatment. Therefore a well-powered trial appears necessary to test the hypothesis that CTx - and more specifically hydrocortisone - could improve day 28 survival of critically-ill patients with severe CAP, severity being assessed either on a Pulmonary Severity Index ≥ 130 (Fine class V) or by the use of mechanical ventilation or high-FiO2 high-flow oxygen therapy. A phase-III multicenter add-on randomized controlled double-blind superiority trial assessing the efficacy of hydrocortisone vs. placebo on Day 28 all-causes mortality, in addition to antibiotics and supportive care, including the correction of hypoxemia. Randomization will be stratified on: (i) centers; (ii) use of mechanical ventilation at the time of inclusion.
Detailed Description
Patients will receive state-of-the-art standard therapy for severe Community-Acquired Pneumonia (CAP), including antibiotics and supportive care. Correction of hypoxemia will use standard low-flow oxygen therapy, high-flow oxygen therapy, non-invasive-ventilation or invasive ventilation with endotracheal tube, as required. Patients in the treatment group will receive intra-venous hydrocortisone. Patients of the control group will receive an intravenous placebo by intravenous route at the same frequency. Hydrocortisone or placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement. A substantial amendment to the CAPE COD study has been submitted to the Competent Authorities in order to conduct a specific analysis on the sub-group of patients included with COVID19 (coronavirus disease 2019), in order to get a quick response in this specific population and in the context of an epidemic emergency. The aim is to answer as quickly as possible a therapeutic question of major importance in the treatment of severe respiratory infections with CoV-2 SARS (severe acute respiratory syndrome coronavirus 2). Modifications made to the original study for patients with COVID (coronavirus disease) include some inclusion criteria, the primary endpoint, and secondary endpoints.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Community Acquired Pneumonia
Keywords
Community-Acquired Pneumonia (CAP), Hydrocortisone, Corticosteroids, COronaVIrus Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
952 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hydrocortisone
Arm Type
Experimental
Arm Description
Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
Intervention Type
Drug
Intervention Name(s)
Hydrocortisone
Intervention Description
Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
Primary Outcome Measure Information:
Title
Day 28 all causes mortality
Time Frame
at day 28
Title
Day 21 failure
Description
For the sub-group of patients included with COVID19, failure is defined as death or need of respiratory support (mechanical ventilation or high-flow oxygen therapy);
Time Frame
at day 21
Secondary Outcome Measure Information:
Title
In patients non-invasively ventilated at inclusion, proportion of patients needing endotracheal intubation
Time Frame
Participants will be followed for the duration of hospital stay, for a maximum of 28 days
Title
In patients non-ventilated at inclusion, proportion of patients requiring non-invasive ventilation
Time Frame
Participants will be followed for the duration of hospital stay, for a maximum of 28 days
Title
In patients non-ventilated at inclusion, proportion of patients needing endotracheal intubation
Time Frame
Participants will be followed for the duration of hospital stay, for a maximum of 28 days
Title
Day 28 ventilator-free-days
Time Frame
between 0 and day 28
Title
Number of patients with vasopressor therapy initiation from inclusion to day 28
Time Frame
between 0 and day 28
Title
Day 28 vasopressor-free-days
Time Frame
between 0 and day 28
Title
ICU and/or intermediate care unit LOS
Time Frame
Participants will be followed for the duration of hospital stay, for a maximum of 28 days
Title
All-causes mortality at day 90
Time Frame
at day 90
Title
SF-36 Health Survey at day 90
Time Frame
at day 90
Title
Biomarkers: procalcitonin at baseline, day 3 and day 7
Time Frame
at inclusion, day 3 and day 7
Title
Biomarkers: C-reactive protein at baseline, day 3 and day 7
Time Frame
at inclusion, day 3 and day 7
Title
Biomarkers: plasmatic concentration of pro-inflammatory cytokines (IL-6, IL-20, IL-22, IL-22BP, HBD2, TNF) at baseline, day 3 and day 7
Time Frame
at inclusion, day 3 and day 7
Title
P/F ratio measured daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28
Time Frame
measured daily from baseline to day 7, at the end of treatment i.e 14 days after the start of treatment, at the end of ICU-stay (for a maximum of 28 days) and/or day 28
Title
SOFA calculated daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28
Time Frame
calculated daily from baseline to day 7, at the end of treatment (i.e 14 days after the start of treatment), at the end of ICU-stay (for a maximum of 28 days) and/or day 28
Title
Proportion of patients experiencing secondary infection during their ICU-stay
Time Frame
Participants will be followed for the duration of hospital stay, for a maximum of 28 days
Title
Proportion of patients experiencing gastrointestinal bleeding during their ICU-stay
Time Frame
Participants will be followed for the duration of hospital stay, for a maximum of 28 days
Title
Daily amount of insulin administered to the patient from day 1 to day 7
Time Frame
Patients will be followed from day 1 to day 7
Title
Weight-gain at baseline and day 7
Time Frame
Patients will be followed at baseline and day 7
Other Pre-specified Outcome Measures:
Title
P/F ratio measured daily from Day1 to Day7, at Day 14 and at Day 21 and/or at the end of ICU-stay
Description
Sub-group of patients included with COVID19
Time Frame
from day 1 to day 7, at day 14 and day 21 and/or at the end of ICU-stay
Title
Proportion of patients needing endotracheal intubation
Description
Sub-group of patients included with COVID19
Time Frame
at day 21
Title
Proportion of patients experiencing secondary infection during their ICU-stay
Description
Sub-group of patients included with COVID19
Time Frame
From baseline to day 21

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Patients affiliated to social security scheme Admission to an Intensive Care Unit (ICU) or intermediate care unit participating to the trial Diagnosis of Community- Acquired Pneumonia (CAP) suggested by at least two of the following: cough, purulent sputum, chest pain and dyspnea Focal shadowing/infiltrate on chest X-ray or CT-scan Diagnosis of Community- Acquired Pneumonia (CAP) during the 48 hours post-hospital admission Study drug infusion initiated no longer than 24 hours post first severity criterion Severity defined by at least one of the following: Pneumonia Severity Index (PSI) > 130 (Fine class V) Patient placed on mechanical ventilation (invasive or not) for acute respiratory failure, with a PEEP level of 5 cm of water or more Patient treated by high-flow oxygen therapy with a FiO2 of 50% or more and a P/F ratio less than 300 Patient treated by oxygen therapy with a partial rebreathing-mask with a reservoir bag, provided that the PaO2 is less than (cf. table): Oxygen flow (L/min) 6 7 8 9 10 or more PaO2 (mmHg) less than 180 210 240 270 300 Patient already treated by antibiotics (at least one dose since admission to hospital) Informed consent signed by the patient, its relatives or emergency procedure On the sub-group of patients included with COVID19 : Diagnosis of COVID19 either as certain (PCR) or probable (evocative clinical and radiological features AND epidemic context AND absence of other microbiological documentation). Study drug infusion initiated no longer than 24 hours post first severity criterion ; in case of transfer from another hospital, this period will be prolonged to 48 hours Patient receiving the best available treatment as define by up-to-date scientific knowledge Exclusion Criteria: Patient treated by vasopressors for septic shock at the time of inclusion Clinical history suggesting of aspiration of gastric content Patient treated by invasive mechanical ventilation within 14 days before current hospital admission Patient treated by antibiotics for a respiratory infection for more than seven days at the admission to the hospital (except if a pathogen resistant to this antibiotics is isolated) History of cystic fibrosis Post-obstructive pneumonia Patients in which rapid PCR-test is positive for flu Active tuberculosis or fungal infection Active viral hepatitis or active infection with herpes viruses Myelosuppression Decision of withholding mechanical ventilation or endotracheal intubation Hypersensitivity to corticosteroids Patient needing anti-inflammatory corticosteroids or substitutive hydrocortisone for any reason Patients under treatment by more than 15 mg/d of prednisone (or equivalent) for more than 30 days Patient already enrolled in another drug trial with mortality as an end-point. If the patient is already participating in another therapeutic trial with a different endpoint, the investigator must verify that inclusion in CAPE COD can not prejudice it. Pregnant or breastfeeding woman Patient on judicial protection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre-François DEQUIN, MD-PhD
Organizational Affiliation
CHRU de TOURS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de Réanimation - Unité de Soins Continus, CH d'Angoulême
City
'Angoulême
ZIP/Postal Code
16959
Country
France
Facility Name
Service de Réanimation Polyvalente, CH d'Argenteuil
City
Argenteuil
ZIP/Postal Code
95107
Country
France
Facility Name
Service de Réanimation, CHR Metz-Thionville
City
Ars-Laquenexy
ZIP/Postal Code
57530
Country
France
Facility Name
Service de Réanimation
City
Aulnay-sous-Bois
ZIP/Postal Code
93602
Country
France
Facility Name
Service de Réanimation
City
Belfort
ZIP/Postal Code
90015
Country
France
Facility Name
Service de Réanimation
City
Bourg-en-Bresse
Country
France
Facility Name
Service de Réanimation HIA Clermont-Tonnerre
City
Brest
ZIP/Postal Code
29240
Country
France
Facility Name
Service de Réanimation Médicale, CHU de Brest
City
Brest
ZIP/Postal Code
29609
Country
France
Facility Name
Service de Réanimation, CHU Côte de Nacre
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Service de Réanimation Médicale, Hôpital Louis Pasteur, Chartres
City
Chartres
ZIP/Postal Code
28000
Country
France
Facility Name
Service de Réanimation Médicale Polyvalente, Hôpital G Montpied
City
Clermont Ferrand
ZIP/Postal Code
63003
Country
France
Facility Name
Service de Réanimation, Hôpital Louis Mourier
City
Colombes
ZIP/Postal Code
92700
Country
France
Facility Name
Service de Réanimation Médicale, CHU de Dijon
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
Service de Réanimation Médico-Chirurgicale, Hôpital Raymond Poincarré, APHP
City
Garches
ZIP/Postal Code
92380
Country
France
Facility Name
Service de Réanimation Médicale, CHU de Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
Service de Réanimation Polyvalente, CHD La Roche sur Yon
City
La Roche sur Yon
ZIP/Postal Code
85925
Country
France
Facility Name
Service de Réanimation, CH Le Mans
City
Le Mans
ZIP/Postal Code
72037
Country
France
Facility Name
Service de Réanimation Polyvalente, Hôpital Salengro, CHU de Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Service de Réanimation Polyvalente, CHU de Limoges
City
Limoges
ZIP/Postal Code
87042
Country
France
Facility Name
Service de Réanimation Médicale, Hôpital Nord
City
Marseille
ZIP/Postal Code
13015
Country
France
Facility Name
Service de Réanimation Polyvalente - Surveillance Continue, CH de Montauban
City
Montauban
ZIP/Postal Code
82013
Country
France
Facility Name
Service de Réanimation Médicale, CHU de Nancy
City
Nancy
ZIP/Postal Code
54511
Country
France
Facility Name
Service de Réanimation Polyvalente, Hôpital Hôtel Dieu, CHU de Nantes
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
Service de Réanimation Médicale, CHR d'Orléans
City
Orléans
ZIP/Postal Code
45067
Country
France
Facility Name
Service de Réanimation Médicale, Hôpital Cochin, APHP
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Name
Service de Réanimation et USC médico-chirurgicale, Hôpital Tenon, APHP
City
Paris
ZIP/Postal Code
75020
Country
France
Facility Name
Service de Réanimation Médicale et Médecine Interne, CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
Service des Maladies Infectieuses et Réanimation Médicale, CHU de Rennes
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
Service de Réanimation Polyvalente, CH de Saint Malo
City
Saint Malo
ZIP/Postal Code
35403
Country
France
Facility Name
Service de Réanimation
City
Saint-Brieuc
ZIP/Postal Code
22000
Country
France
Facility Name
Service de Réanimation Médicale, Nouvel Hôpital Civil, CHU de Strasbourg
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Service de Réanimation Médicale, Hôpital de Hautepierre, CHU de Strasbourg
City
Strasbourg
ZIP/Postal Code
67098
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32876689
Citation
Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G, Badie J, Francois B, Aubron C, Ricard JD, Ehrmann S, Jouan Y, Guillon A, Leclerc M, Coffre C, Bourgoin H, Lengelle C, Caille-Fenerol C, Tavernier E, Zohar S, Giraudeau B, Annane D, Le Gouge A; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
Results Reference
derived

Learn more about this trial

Community-Acquired Pneumonia : Evaluation of Corticosteroids

We'll reach out to this number within 24 hrs